Downloading...
Download

ATNX

ATNX Technical Analysis 🧙Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
ALong
by trading_as_bus
Athenex, Inc (ATNX)(Nasdaq) Buy Limit $11.30 >>> Target $12.10Nasdaq:ATNX Athenex, Inc Last News: Athenex partner in China on go to launch TAEST therapy studies; shares up 2% Athenex (ATNX +2.1%) announces that commercialization partner Xiangxue Pharmaceutical Company's subsidiary Xiangxue Life Sciences has received regulatory sign-off in China to start registration studies of T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy (candidate TAEST16001) in patients with solid tumors that are HLA-A*02:01-positive and NY-ESO-1-positive. In July 2018, the companies established a joint venture, Axis Therapeutics Limited, to develop the TAEST technology. --- Buy Limit - $11.30 Take Profit - $12.10 Stop Loss - $10.89 ------ Take Profit = +7.17% Stop Loss = -3.54%
ALong
by UnknownUnicorn285026